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Abstract
Background: Studies evaluating the association between alcohol intake and ovarian carcinoma (OC) are
inconsistent. Because OC and ovarian borderline tumor histologic types differ genetically, molecularly and clinically,
large numbers are needed to estimate risk associations.
Methods: We pooled data from 12 case-control studies in the Ovarian Cancer Association Consortium comprising
5,342 OC cases, 1,455 borderline tumors and 10,358 controls with quantitative information on recent alcohol intake
to estimate odds ratios (OR) and 95% confidence intervals (CI) according to frequencies of average daily intakes of
beer, wine, liquor and total alcohol.
Results: Total alcohol intake was not associated with all OC: consumption of >3 drinks per day compared to none,
OR=0.92, 95% CI=0.76-1.10, P trend=0.27. Among beverage types, a statistically non-significant decreased risk was
observed among women who consumed >8 oz/d of wine compared to none (OR=0.83, 95% CI=0.68-1.01, P
trend=0.08). This association was more apparent among women with clear cell OC (OR, 0.43; 95% CI, 0.22-0.83;
P trend=0.02), although based on only 10 cases and not statistically different from the other histologic types (P
value for statistical heterogeneity between histologic types = 0.09). Statistical heterogeneity of the alcohol- and
wine-OC associations was seen among three European studies, but not among eight North American studies. No
statistically significant associations were observed in separate analyses evaluating risk with borderline tumors of
serous or mucinous histology. Smoking status did not significantly modify any of the associations.
Conclusions: We found no evidence that recent moderate alcohol drinking is associated with increased risk for
overall OC, or that variation in risk is associated strongly with specific histologic types. Understanding modifiable
causes of these elusive and deadly cancers remains a priority for the research community.
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Carcinomas classified as ovarian are the fourth most
common female cancer, accounting for 225,000 (3.7%) of
all new cases and 140,000 (4.2%) of all cancer deaths glo-
bally [1]. Known mutations in high penetrance genes are
the best-defined risk factors, explaining ~10-15% of all
epithelial ovarian carcinomas [2-6], while common var-
iants in low penetrance genes may account for a smal-
ler fraction (~3%) of the polygenic component [7-9].
Non-genetic factors associated with the development of
ovarian carcinoma include reduced risk with oral contra-
ceptive use [10,11], number of full-term pregnancies
[12,13], long-term breastfeeding [14] and tubal ligation
or salpingectomy in BRCA1/2 mutation carriers [12].
The independent contribution of modifiable environ-
mental [15,16] and lifestyle or behavioral [17-21] factors
including diet is inconclusive, and only a few studies
have confirmed non-genetic risk factor associations
according to histologic type [14,22-25].
Several studies examined the association between total
alcohol consumption and ovarian carcinoma and reported
inverse [17,26,27], null [28-31], or positive [32,33] trends
with the highest category of alcohol intake. Increased risk
was also found among the mucinous histologic type
[34,35]. An earlier pooled analysis of prospective studies
found no association between ≥30 g/d total alcohol intake
compared to 0 g/d among 2,001 cases of ovarian carcin-
oma (RR, 1.12; 95% CI, 0.86-1.44), or for alcohol modeled
continuously among 121 cases with mucinous histology
(RR, 1.06; 95% CI, 0.84-1.34) [36]. A previous meta-
analysis reported no overall association between alcohol
consumption and ovarian carcinoma, but did find a 6%
increased risk of mucinous ovarian carcinomas (95% CI,
1.01, 1.12, n=581) with each increase in intake of 10 g/day
alcohol using continuous estimates obtained from authors
of primary reports [37]. A more recent meta-analysis of 27
observational studies found no overall association of mod-
erate or heavy drinking, but found an inverse trend with
endometrioid ovarian carcinoma from three studies
reporting associations by histology [38]. Two other reports
summarized the epidemiologic evidence of the relation be-
tween alcohol and ovarian carcinoma descriptively [39]
and as a systematic review [27]. Reviews or meta-analytic
techniques that summarize categorical data from primary
investigations comparing highest to lowest intakes have
several limitations, including a loss of data when inter-
mediate intake categories are excluded, which may intro-
duce reporting bias, a problem termed “publication bias in
situ” [40]. Additionally, primary studies differ in their ad-
justment for important confounders, in whether they dis-
tinguish invasive cancers from borderline tumors, which
differ genetically, molecularly and clinically [41,42], and in
whether they reported associations separately by histologic
type. These differences challenge the ability to synthesize
published findings. To circumvent these limitations, we
conducted a large pooled analysis of original data from 12
studies participating in the Ovarian Cancer Association
Consortium (OCAC).
Methods
Study subjects
Twelve studies of ovarian cancer that contributed data
are described in Table 1. All studies used population-
based ascertainment methods for identifying eligible
cases and controls and most studies matched cases to
controls on age or age and region of residence. Eight
studies were from the United States or Canada (CON
[43], DOV [44], HAW [45], HOP [46], NCO [47,48],
NEC [49,50], NJO [51,52] and SON [53]), three were
from Europe (GER [54], MAL [55-57] and POL [58])
and one was from Australia (AUS [59]). Informed con-
sent was obtained from participating subjects in each of
the individual studies, and local human research investi-
gations committees approved each study.
Alcohol assessment and covariate data collection
The unit of analysis for alcohol consumption was aver-
age daily grams of alcohol intake (g/d). Daily alcohol in-
take was estimated using validated food frequency
questionnaires (FFQs) in AUS [60], DOV [61], HAW
[62], MAL, NEC [63], NJO [51] and SON [53]. The ex-
posure period was the year preceding recruitment (AUS,
HAW, MAL, NEC, NJO and SON) or the time period
approximately four years before the reference date
(DOV). The remaining studies did not use FFQs but em-
bedded questions regarding alcohol intake in risk factor
questionnaires (CON [43], GER, HOP [34], NCO and
POL). The exposure period for these studies was habit-
ual regular drinking at the reference date (HOP) or the
time period approximately five years before the reference
date (CON, GER, NCO and POL). Daily alcohol intake
for all studies was calculated by summing the product of
the frequency of consumption of a specified serving of
alcoholic beverage (beer, wine and liquor) by the alcohol
content of that beverage using national estimates of al-
cohol content for that country. Total alcohol was esti-
mated as the sum of alcohol intake across all alcoholic
beverage types and submitted for pooled analysis. A sub-
set of studies (AUS, CON, DOV, HAW, HOP and NEC)
provided information for white and red wine separately.
Key clinical, demographic and questionnaire data on
study subjects were merged into a common dataset and
included case-control status, ethnicity/race, tumor be-
havior and histology, age at diagnosis (or comparable
reference date for controls), history of prior cancers,
current/former/never smoking status, menopausal sta-
tus, oral contraceptive use, tubal ligation, endometriosis,
hysterectomy, family history of breast or ovarian cancer
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Study
acronym
Study name Controls,
n
Cases, n White non-
Hispanic %
*
Carcinoma cases
with grade
information %†
Recruitment
year and
location
Matching variables‡
Border-
line
All
carcinomas§
Serous Muc-
inous
Endo-
metrioid
Clear
Cell
AUS [59] AOCS (Australian Ovarian Cancer
Study) and ACS (Australian
Cancer Study – Ovarian Cancer)
1,333 259 882 537 39 106 71 93.3 92.8 2002-2006;
Australia
State of residence and 5-
year age groups
CON [43] CON (Connecticut Ovarian Cancer
Study)
526 103 339 193 18 70 33 91.7 85.4 1998-2003;
Connecticut, USA
3 age strata (35-49, 50-64
and 65-79 years)
DOV [44] DOVE (Diseases of the Ovary and
their Evaluation)
1,116 189 483 269 20 81 31 90.9 82.7 2002-2005 and
2006-2009;
Washington, USA
5-year age groups, 1-year
calendar intervals and
two county strata
GER [54] GOCS (German Ovarian Cancer
Study)
502 30 209 107 24 23 6 99.9 100 1993-1996;
Germany
Age and study region
HAW [45] HAWAII (Hawaii Ovarian Cancer
Study)
1,100 97 384 176 42 68 50 31.9 91.3 1993-2008;
Hawaii, USA
5-year age groups and
race
HOP [46] HOPE (Hormones and Ovarian
Cancer Prediction Study)
1,365 76 530 289 27 71 46 96.0 94.1 2003-2009;
Pennsylvania, USA
5-year age groups and
area code plus 3
number prefix
MAL [55-
57]
MALOVA (Malignant Ovarian
Cancer Study)
908 115 267 157 30 41 21 100 93.9 1994-1999;
Denmark
5-year age groups
NCO
[47,48]
NCOCS (North Carolina Ovarian
Cancer Study)
979 212 777 429 44 126 82 80.9 100 1999-2008; North
Carolina, USA
5-year age groups and
race
NEC
[49,50]
NECC (New England-based Case-
Control Study)
1,109 274 707 386 47 152 96 96.3 100 1992-1997 and
1998-2003; New
England, USA
5-year age groups and
region of residence
NJO
[51,52]
NJOCS (New Jersey Ovarian
Cancer Study)
277 0 183 104 7 30 24 87.6 87.2 2002-2008; New
Jersey, USA
None
POL [58] POL (Polish Ovarian Cancer
Control Study)
601 18 236 101 25 52 13 100 66.3 2000-2003;
Poland
5-year age groups and
study center
SON [53] SON (Southern Ontario Study of
Reproduction, Diet and Health)
542 82 345 200 38 65 28 98.3 0 1989-1992;
Southern Ontario
3 age strata (35-49, 50-64
and 65-79 years)
Totals 10,358 1,455 5,342 2,948 361 885 501 87.7 84.86
* White non-Hispanic subjects as a percentage of all race-ethnicities enrolled in each study.
† Percentages reflect grade available for serous, mucinous and endometrioid carcinomas and for which we applied the algorithm to reduce histologic misclassification (see Methods).
‡ All studies except GER used frequency matching.
§ Includes the epithelial histologic types: serous, mucinous, endometrioid, clear cell, mixed epithelial, transitional cell, squamous cell, and undifferentiated.
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8in first-degree relatives, parity, age at last parturition,
interview year, age at menarche, body mass index (BMI)
and study site. Total energy intake was obtained from
studies that collected dietary information using FFQs
(AUS, DOV, HAW, NEC, NJO and SON). The data were
checked for consistency and completeness and discrepan-
cies were followed-up with individual study investigators.
We excluded from analyses subjects with non-
epithelial ovarian tumors, prior histories of cancer other
than non-melanoma skin cancer or subjects with miss-
ing information for total alcohol intake. Data were avail-
able from 5,342 cases of incident ovarian carcinoma,
1,455 women with incident ovarian borderline tumors
and 10,358 controls (Table 1).
Statistical analysis
The studies were combined into a single dataset for ana-
lysis. Alcohol intake categories were derived in increments
of one standard drink (g ethanol content) consumed daily:
alcohol from any source (10 g); 12 oz beer (12.2 g), 4 oz
wine (10.5 g) and 1 oz liquor (9.5 g). Primary analyses
evaluated associations between alcohol intake and risk of
ovarian carcinoma (excluding borderline tumors) using
unconditional logistic regression to estimate odds ratios
(OR) and 95% confidence intervals (CI). Trends in risk
were evaluated by modeling the ordinal variable represent-
ing the category values of alcohol intake (e.g., 1, 2, 3)
in the regression models with 1 degree-of-freedom [64].
Statistical heterogeneity in ORs across studies was evalu-
ated using the likelihood ratio test comparing models with
and without an interaction term between alcohol intake
and study site. To describe further the degree of statistical
heterogeneity, we estimated I
2, the between-group vari-
ance [65], which describes the proportion of total variation
in estimates of the ORs due to the heterogeneity between
groups of studies. We estimated I
2 to evaluate statistical
heterogeneity between studies defined by their continent
of origin. Groups of studies with statistically homogeneous
ORs have an I
2 value of zero.
All models were adjusted for the known or potential
confounders footnoted in the tables. Risk models asso-
ciated with total alcohol intake did not include other al-
coholic beverage types. Risk models associated with beer,
wine or liquor intake included all three beverage types
and were thus adjusted for each other. Risk models asso-
ciated with white or red wine intake included both types
of wine as well as beer and liquor intake. To account for
potential heterogeneity of summary risk estimates across
studies, all models included interaction terms between
every non-alcohol covariate and study site and are thus
equivalent to fixed-effects meta-analyses, although the
exclusion of these terms did not alter the risk estimates
appreciably (data not shown). In addition, among a sub-
set of studies, primary analyses were also adjusted for
total energy intake, excluding subjects with extreme total
energy values as previously described [66] and using the
residual method [67], in order to evaluate the extent of
confounding from this variable.
For the 12 studies combined, we simultaneously mod-
eled the risk of each of five histologic types of ovarian
carcinoma (high-grade serous, low-grade serous, mucin-
ous, endometrioid and clear cell) and two of the four
main types of borderline tumors with sufficient numbers
for analysis (serous and mucinous) using polytomous lo-
gistic regression [68]. Risk models were adjusted for all
covariates but excluded the interactions between non-
alcohol covariates and study site to ease statistical com-
putation. Statistical heterogeneity of the alcohol-ovarian
tumor histology associations was tested separately for
the carcinomas and the borderline tumors and was eval-
uated using the type 3 analysis of effects with degrees-
of-freedom equal to the number of response levels
minus one times the number of exposure levels minus
one [68]. For these models, we incorporated considera-
tions from the contemporary pathology literature to re-
fine risk associations in the analyses of histologic type,
as implemented previously [69]. Specifically, others have
shown that an appreciable proportion of grade 3 mucin-
ous ovarian carcinomas are, in fact, metastatic from the
gastrointestinal tract [70], up to one-third of endome-
trioid ovarian carcinomas are high-grade serous ovarian
carcinomas [71,72] and approximately 3% of epithelial
ovarian carcinomas are low-grade serous [71,72]. We,
therefore, re-assigned histologic type according to the
expected distributions of histology combined with grade
observed from large population-based series [71,72] as
follows. Endometrioid carcinomas were re-classified as
high-grade serous carcinomas if their grade was ≥G3,
mucinous carcinomas were assumed to be metastatic
and excluded from analysis if ≥G3, and serous histology
was re-classified as either low-grade serous carcinomas
(G1) or high-grade serous carcinomas (≥G2).
Because of the reported association between smoking
and ovarian carcinoma and, particularly for mucinous
ovarian carcinoma and mucinous borderline tumors
[22,24,25], statistical interaction was evaluated using the
likelihood ratio test comparing models with and without
an interaction term for the categorical forms of alcohol
intake and smoking status (never, current and former).
We also performed stratified analyses of alcohol intake
across categories of smoking status. Potential modifica-
tion of the alcohol-ovarian carcinoma association by
other variables was examined using a similar approach.
Statistical tests were two-sided and implemented with
SAS (SAS Institute, Cary, NC, Version 9.1). Funnel plots
representing the study-specific and combined data esti-
mates were derived from the logistic regression models
as described above.
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Characteristics of included studies and participants
Table 1 describes the characteristics of the 12 case-control
studies. Eighty-eight percent of the cases were white non-
Hispanic and ~85% of the carcinomas had information on
tumor grade. The distribution of alcohol intake is shown
in Additional file 1: Table S1, overall and for each study
separately. Overall, average daily total alcohol intake ran-
ged from approximately one-fifth of a standard drink at
the 25
th percentile to 1-2 drinks at the 75
th percentile of
the distributions. More women consumed wine than the
other alcoholic beverages.
Generally, cases and controls were similar in their dis-
tributions across covariates (Additional file 1: Table S2).
As expected, however, cases were more frequently post-
menopausal than controls, were more likely to be nul-
liparous, and less likely than controls to have used oral
contraceptive hormones for appreciable durations or to
have had tubal ligation or a hysterectomy. The majority
(~75%) of subjects were recruited in the past decade.
The distribution of covariates did not differ by much
among controls who consumed beer, wine or liquor ex-
cept, perhaps, that fewer wine consumers were current
smokers and a greater proportion of beer drinkers were
pre- or peri-menopausal.
Alcohol consumption and risk of ovarian carcinoma
In multivariable-adjusted pooled analyses, total alcohol
intake from any source was not associated with risk of
ovarian carcinoma (consumption of >3 drinks per
day compared to none: OR=0.92, 95% CI=0.76-1.10,
P trend=0.27; Table 2). Given the absence of a dose-
response relationship, we modeled the variable dichot-
omously (none, any regular consumption) (Figure 1).
Adjustment for known or suspected confounders be-
yond age and race (Figure 1A) tended to attenuate risk
associations (Figure 1B) indicating the importance of
accounting for these variables in the analysis. Further ad-
justment for total energy had little effect (data not shown).
Alcoholic beverage type and risk of ovarian carcinoma
All studies provided information on type of alcoholic bever-
age consumed (beer, wine and liquor). Compared to
women who reported no wine intake, we observed
a statistically non-significant decreased risk associated with
c o n s u m p t i o no fm o r et h a n8o z / do fw i n ea f t e ra d j u s t i n g
Table 2 Association between consumers of alcoholic
beverages and ovarian carcinoma, OCAC studies
Intake/d Ca/Co OR (95% CI)
Total alcohol 5,342/10,358
None 2,269/4,296 1.0 (Ref)
Up to 1 drink * 2,074/3,928 0.94 (0.85-1.03)
1-2 drinks 560/1,112 0.97 (0.85-1.11)
2-3 drinks 192/400 0.91 (0.74-1.11)
>3 drinks 247/622 0.92 (0.76-1.10)
P trend 0.27
Beer†
None 4,016/7,472 1.0 (Ref)
Up to 12 oz 1,179/2,570 0.92 (0.83-1.02)
>12 oz 147/315 1.09 (0.86-1.37)
P trend 0.43
Wine†
None 2,821/5,307 1.0 (Ref)
Up to 4 oz 2,057/3,984 0.94 (0.85-1.04)
4-8 oz 261/522 1.00 (0.83-1.20)
>8 oz 203/545 0.83 (0.68-1.01)
P trend 0.08
White wine‡
None 2,110/4,114 1.0 (Ref)
Up to 4 oz 1,053/2,032 0.93 (0.82-1.06)
>4 oz 162/406 0.97 (0.77-1.21)
P trend 0.26
Red wine‡
None 2,330/4,548 1.0 (Ref)
Up to 4 oz 866/1,665 0.92 (0.81-1.05)
>4 oz 129/336 0.90 (0.71-1.15)
P trend 0.11
Liquor†
None 3,599/6,865 1.0 (Ref)
Up to 1 oz 1,535/3,061 0.97 (0.88-1.08)
>1 oz 208/431 1.03 (0.85-1.26)
P trend 0.82
Adjusted for age (<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never,
former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO,
POL, SON), race/ethnicity (white nonHispanic; white Hispanic; black non
Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal;
postmenopausal, unknown or missing), oral contraceptive use (<6mo, 6-22
mo, 23+ mo, unknown or missing), tubal ligation (yes; no; unknown or
missing), endometriosis (yes; no; unknown or missing), hysterectomy (yes; no;
unknown or missing), family history of breast or ovarian cancer in first-degree
relatives (no; yes; unknown; no daughters or sisters), parity/age at last birth
(nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at
last pregnancy; 1-2 births/age >25 years at last pregnancy; 3+ births/age
>25 years at last pregnancy; yes if ever pregnant but unknown or missing age
at last pregnancy age; no or unknown if ever pregnant and missing age at last
pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009;
missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs; 13 yrs; 14-21 yrs; <8 or ≥
22 yrs), body mass index (continuous) and education (less than high school,
high school, some college, completed college or university, completed
graduate or professional degree, missing). Models include interaction terms
between site and each covariate except alcohol.
* 1 drink = 10 grams ethanol.
† Models are also simultaneously adjusted for consumption of beer, wine and
liquor intake.
‡ White/red wine information available from AUS, CON, DOV, HAW, HOP and
NEC only. Models are simultaneously adjusted for beer and liquor intake.
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(OR=0.83, 95% CI=0.68-1.01, P trend=0.08; Table 2). Asso-
ciations did not differ by much when we restricted the ana-
lyses to those individuals who consumed only one type of
alcoholic beverage (data not shown). Among a subset of
studies with information on white or red wine consumed,
risk associations were not statistically significant.
Alcohol and ovarian tumor histologic types
More than 3 average drinks/d of alcohol intake from any
source was associated with a lower risk of endometrioid
ovarian carcinoma (OR=0.49, 95% CI=0.27-0.91), although
this was no longer evident when the two highest intake
categories were combined (>2 drinks/d: OR=0.85, 95%
CI=0.58-1.26; P trend=0.45; Table 3). We observed a
statistically significant inverse trend between consumption
of wine and clear cell ovarian carcinomas with a decreased
risk at higher intakes only (>8 oz/d: OR=0.43, 95%
CI=0.22-0.83; P trend=0.02). This association, however,
was based on 10 cases and the heterogeneity between
histologic types was not statistically significant (P hetero-
geneity=0.09). Following combining the two highest intake
categories, the association remained suggestive (>4 oz/d:
OR=0.70, 95% CI=0.47-1.03, P trend=0.05; Table 3). A sta-
tistically non-significant increased risk was also seen be-
tween total alcohol intake over 3 average drinks/d and
mucinous borderline tumors (OR=1.40, 95% CI=0.99-1.20;
P trend=0.22, Table 4, data shown for total alcohol and
wine only) but disappeared following combining the two
highest intake categories (>4 oz/d: OR=1.22, 95% CI=0.90-
1.66, P trend=0.42; Table 4). Application of the pathology-
based algorithm tended to shift estimates and 95% CIs
farther from the null, although there was no appreciable
difference in significance of estimates when the algorithm
was not implemented (Additional file 1: Table S3).
Potential sources of effect modification
The association between total alcohol intake (none, any
regular consumption) and risk of ovarian carcinoma var-
ied somewhat across studies following multivariable ad-
justment (Figure 1B, P interaction=0.03); the source of
heterogeneity was within the three European studies
when evaluated by continent of study origin (within-
group heterogeneity: Europe, I
2=75%; North America,
I
2=0%). The association between wine intake (none, any
regular consumption) and risk of ovarian carcinoma also
varied across studies following multivariable adjustment
(P interaction=0.01) and significant heterogeneity was
again observed within the European studies (I
2=81%).
Within North American studies, the estimates for wine
intake were statistically homogeneous for ovarian carcin-
oma overall (OR, 0.99; 95% CI, 0.89-1.10; I
2=0%). We
evaluated whether the decreased risk observed between
wine intake and clear cell carcinomas (Table 3) was
influenced by the variability within European studies by
excluding the three European studies. The association
between consumption of >8 oz/d wine and clear cell
ovarian carcinomas remained significant (OR=0.48, 95%
CI=0.25-0.95; P trend=0.03; 10 cases). Alcohol, in gen-
eral, has been reported to reduce cellular proliferation
by influencing the insulin and insulin-like growth factor
(IGF) pathways [73,74], and these pathways have been
implicated in the early development and prognosis of
clear cell carcinoma types [75-78]. Because obesity is
associated with impaired insulin sensitivity [74], we
tested the trend association of alcohol or wine intake with
histologic types stratified by BMI (<30 vs ≥30 kg/m
2).
There was no clear effect modification by BMI among any
of the histologic types for total alcohol intake (data not
NJO 0.78 0.47 -1.30
GER 0.48 0.34 -0.67
POL 1.16 0.83 -1.62
MAL 0.91 0.56 -1.48
CON 0.80 0.56 -1.15
SON 1.03 0.78 -1.36
HAW 0.78 0.59 -1.04
DOV 0.83 0.67 -1.03
HOP 1.08 0.82 -1.43
NEC 0.86 0.70 -1.06
NCO 1.00 0.82 -1.22
AUS  0.66 0.53 -0.82
0.5 1 2
A
NJO 0.96 0.56 -1.67
GER 0.48 0.32 -0.71
POL 1.19 0.64 -2.22
MAL 0.98 0.58 -1.64
CON 0.89 0.60 -1.33
SON 1.22 0.86 -1.73
HAW 1.05 0.77 -1.44
DOV 0.91 0.72 -1.15
HOP 1.11 0.82- 1.51
NEC 0.96 0.76 -1.20
NCO 1.10 0.88 -1.38
AUS  0.75 0.59 -0.94
0.5 12
B
Figure 1 Funnel plot of study-specific and summary OR and
95% CI for the association between alcohol intake (none, any)
and ovarian carcinoma in 12 OCAC studies. Squares indicate
study-specific OR; the size of the squares is proportional to study-
specific sample size; the width of lines indicates the study-specific
95% CI; diamonds indicate summary OR; the width of the diamonds
indicates summary 95% CI. Refer to Table 1 for study nomenclature.
1A: Age and race adjusted OR and 95% CI. Statistical heterogeneity
in ORs across studies, P value < 0.0001 (see Statistical analysis). 1B:
Multivariable-adjusted OR and 95% CI. Adjusted for variables in
footnote of Table 2. Statistical heterogeneity in ORs across studies, P
value = 0.03.
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http://www.biomedcentral.com/1471-2407/13/28Table 3 Association between total alcohol and wine intake and histological types* of ovarian carcinoma, OCAC studies
Intake/d Controls
N=10,358
High-Grade Serous
N=2,580
Mucinous
N=245
Endometrioid
N=506
Clear Cell N=501 Low-Grade Serous
N=198
Co Ca OR (95% CI) Ca OR (95% CI) Ca OR (95% CI) Ca OR (95% CI) Ca OR (95% CI) P value†
Total alcohol ‡
None 4,296 1,060 1.0 (Ref) 98 1.0 (Ref) 214 1.0 (Ref) 223 1.0 (Ref) 61 1.0 (Ref)
Up to 1 drink 3,928 1,029 0.95 (0.84-1.07) 97 1.08 (0.76-1.52) 207 0.97 (0.76-1.23) 188 0.84 (0.66-1.07) 90 0.95 (0.65-1.38)
1-2 drinks 1,112 282 0.97 (0.83-1.15) 26 1.08 (0.66-1.75) 50 0.96 (0.68-1.36) 53 0.97 (0.69-1.37) 29 1.28 (0.78-2.11)
2-3 drinks 400 79 0.78 (0.60-1.02) 11 1.36 (0.69-2.67) 23 1.36 (0.85-2.19) 17 0.96 (0.56-1.63) 8 0.98 (0.45-2.13)
>3 drinks 622 130 0.96 (0.77-1.20) 13 0.98 (0.52-1.82) 12 0.49 (0.27-0.91) 20 0.82 (0.50-1.34) 10 1.12 (0.55-2.29)
P trend 0.31 0.71 0.25 0.50 0.54 0.67
>2 drinks§ 1,022 209 0.88 (0.74-1.06) 24 1.12 (0.69-1.83) 35 0.85 (0.58-1.26) 37 0.88 (0.60-1.30) 18 1.05 (0.59-1.86)
P trend § 0.24 0.62 0.45 0.52 0.53 0.71
Wine
None 5,307 1,316 1.0 (Ref) 128 1.0 (Ref) 263 1.0 (Ref) 272 1.0 (Ref) 81 1.0 (Ref)
Up to 4 oz 3,984 1,022 0.93 (0.83-1.04) 103 1.12 (0.81-1.54) 206 0.96 (0.77-1.21) 195 0.87 (0.69-1.09) 91 0.94 (0.66-1.34)
4-8 oz 522 129 0.93 (0.75-1.16) 10 1.03 (0.52-2.04) 22 0.98 (0.61-1.58) 24 0.95 (0.60-1.50) 13 1.33 (0.70-2.50)
>8 oz 545 113 0.86 (0.68-1.09) 4 0.39 (0.14-1.09) 15 0.68 (0.39-1.20) 10 0.43 (0.22-0.83) 13 1.35 (0.71-2.56)
P trend 0.13 0.32 0.29 0.02 0.34 0.09
>4 oz § 1,067 242 0.89 (0.75-1.06) 14 0.70 (0.39-1.27) 37 0.84 (0.57-1.23) 34 0.70 (0.47-1.03) 26 1.34 (0.81-2.20)
P trend § 0.13 0.61 0.41 0.05 0.44 0.25
Adjusted for age (<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never, former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, POL, SON), race/ethnicity (white nonHispanic; white Hispanic;
black non Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal; postmenopausal, unknown or missing), oral contraceptive use (<6mo, 6-22 mo, 23+ mo, unknown or missing), tubal ligation
(yes; no; unknown or missing), endometriosis (yes; no; unknown or missing), hysterectomy (yes; no; unknown or missing), family history of breast or ovarian cancer in first-degree relatives (no; yes; unknown; no
daughters or sisters), parity/age at last birth (nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at last pregnancy; 1-2 births/age >25 years at last pregnancy; 3+ births/age >25 years at last
pregnancy; yes if ever pregnant but unknown or missing age at last pregnancy age; no or unknown if ever pregnant and missing age at last pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009;
missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs; 13 yrs; 14-21 yrs; <8 or ≥ 22 yrs), body mass index (continuous) and education (less than high school, high school, some college, completed college or university,
completed graduate or professional degree, missing).
* Cases restricted to samples with information on grade for serous, mucinous and endometrioid histologic types, and for whom we applied the algorithm to reduce histologic misclassification (see Methods).
† P for tumor heterogeneity derived from testing the trend variable for alcohol or wine intake in polytomous regression models with 5 df (see Statistical analysis).
‡ 1 drink = 10 grams ethanol.
§ Risk estimates and P trend values are from models that collapse the two highest intake categories.
Models are also simultaneously adjusted for consumption of beer and liquor intake.
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8shown), and suggestive decreased risks for wine intake at
lower BMI for both clear cell carcinomas (BMI <30 kg/m
2:
OR=0.83, 95% CI=0.69-1.00; n=382 cases vs BMI ≥30 kg/
m
2: OR=0.79, 95% CI=0.53-1.18; n=119 cases) and high-
grade serous carcinomas (BMI <30 kg/m
2:O R = 0 . 9 0 ,9 5 %
CI=0.83-0.98; n=2,052 cases vs BMI ≥30 kg/m
2:O R = 1 . 1 7 ,
95% CI=0.96-1.42; n=528 cases). Smoking status did not
significantly modify the association between ovarian
carcinoma and total alcohol intake (P interaction=0.11) or
wine intake (P interaction=0.97) (Additional file 1:
Table S4) or between mucinous borderline tumors and
total alcohol intake (data not shown). None of the other
covariates statistically modified the alcohol- or wine-
ovarian carcinoma association including race/ethnicity
(P interactions ≥ 0.22) (data not shown).
Discussion
While current guidelines for cancer prevention restrict
alcohol drinking for women to no more than 1 drink per
day [79], we found no evidence that recent moderate al-
cohol drinking increased overall ovarian carcinoma risk.
Although there was some indication of effect modifica-
tion by cell type, the statistical evidence was weak. This
is the largest study to date to perform this evaluation
quantitatively across the five types of ovarian carcinomas
and the two groups of borderline ovarian tumors using
individual-level data on alcohol intake.
Various oncogenic mechanisms of alcohol are well
documented [80]. Although the evidence is convincing
that alcohol is a risk factor for cancers of the breast and
several cancers of the gastrointestinal tract [81], it has
been equivocal for ovarian cancer [17,26-33]. Overall,
our investigation adds to the evidence that recent mod-
erate alcohol consumption is not significantly associated
with ovarian carcinoma. A number of design and ana-
lytic factors can lead to disparate findings across studies.
For example, heterogeneity of risk estimates were
observed in European studies, a finding also reported by
others [38]. The type and range of alcohol intake varies
considerably across European countries and should be
interpreted carefully when data are pooled or evaluated
meta-analytically across continents.
Table 4 Association between total alcohol and wine intake and ovarian borderline tumors, OCAC studies
Intake/d Controls N=10,358 Serous borderline N=818 Mucinous borderline N=561
Total alcohol * Ca OR (95% CI) Ca OR (95% CI) P value†
None 4,296 297 1.0 (Ref) 181 1.0 (Ref)
Up to 1 drink 3,928 349 0.87 (0.72-1.05) 245 0.95 (0.76-1.20)
1-2 drinks 1,112 86 0.91 (0.69-1.20) 59 0.86 (0.62-1.20)
2-3 drinks 400 32 1.04 (0.69-1.56) 23 0.94 (0.58-1.51)
>3 drinks 622 54 1.19 (0.86-1.66) 53 1.40 (0.99-1.20)
P trend 0.45 0.22 0.39
>2 drinks § 1,022 86 1.13 (0.86-1.49) 76 1.22 (0.90-1.66)
P trend § 0.63 0.42 0.67
Wine
None 5,307 405 1.0 (Ref) 263 1.0 (Ref)
Up to 4 oz 3,984 336 0.89 (0.74-1.06) 236 0.89 (0.72-1.10)
4-8 oz 522 38 0.99 (0.68-1.43) 26 0.88 (0.57-1.36)
>8 oz 545 39 0.99 (0.69-1.44) 36 1.03 (0.69-1.52)
P trend 0.66 0.72 0.87
>4 oz § 1,067 77 0.99 (0.75-1.31) 62 0.96 (0.70-1.31)
P trend § 0.52 0.52 0.69
Adjusted for age (<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never, former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, POL,
SON), race/ethnicity (white nonHispanic; white Hispanic; black non Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal; postmenopausal,
unknown or missing), oral contraceptive use (<6mo, 6-22 mo, 23+ mo, unknown or missing), tubal ligation (yes; no; unknown or missing), endometriosis (yes; no;
unknown or missing), hysterectomy (yes; no; unknown or missing), family history of breast or ovarian cancer in first-degree relatives (no; yes; unknown; no
daughters or sisters), parity/age at last birth (nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at last pregnancy; 1-2 births/age
>25 years at last pregnancy; 3+ births/age >25 years at last pregnancy; yes if ever pregnant but unknown or missing age at last pregnancy age; no or unknown if
ever pregnant and missing age at last pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009; missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs;
13 yrs; 14-21 yrs; <8 or ≥ 22 yrs), body mass index (continuous) and education (less than high school, high school, some college, completed college or university,
completed graduate or professional degree, missing). Wine consumption was additionally adjusted for other alcoholic beverage types. Models include interaction
terms between site and each covariate except alcohol.
* 1 drink = 10 grams ethanol.
† P for tumor heterogeneity derived from testing the trend variable for alcohol or wine intake in polytomous regression models with 2 df (see Statistical analysis).
§ Risk estimates and P trend values are from models that collapse the two highest intake categories.
Models are also simultaneously adjusted for consumption of beer and liquor intake.
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http://www.biomedcentral.com/1471-2407/13/28Previous studies reported decreased risk from wine in-
take [26,27,31,82], although most associations were not
statistically significant. The most widely reported consti-
tuents in wine are the polyphenols, including resveratrol,
which derive mainly from the aerial tissues (grape skin)
because their biosynthesis is stimulated by light [83].
Numerous anticarcinogenic properties of the polyphe-
nols have been proposed [84]. A potentially interesting
finding in the current study is the association between
higher recent intakes of wine with decreased risk of clear
cell ovarian carcinoma. The association persisted follow-
ing exclusion of the European studies. A decreased risk
from wine, but not beer or liquor, intake was also found
among women in a pooled analysis of 12 prospective
studies of renal cell carcinoma [85]. Clear cell ovarian
carcinomas share similar features with clear cell renal
cell carcinomas [86-88] and it has been suggested that
moderate alcohol intake may improve insulin sensitivity
and regulate related pathways [73,74] that are implicated
in the etiology of these carcinomas [75-78]. We observed
suggestive decreased risks of wine intake among non-
obese women for clear cell and high-grade serous ovar-
ian carcinomas; however, we cannot exclude the possi-
bility that these findings are due to chance.
Several key non-genetic risk factors for ovarian cancer
were reported in the early 1990s, when studies established
decreased risks associated with oral contraceptive use
[10,11], parity [12,13] and breast-feeding [12]. Using our
consortium data, we recently reported that endometriosis
was associated with increased risk of endometrioid and
clear cell ovarian carcinomas [23]. However, few modifiable
risk factors for ovarian cancers have been found. Perhaps
the only lifestyle factor that is most consistently associated
with modified risk of ovarian cancers is smoking, which is
associated with an increased risk of both mucinous ovarian
carcinoma and mucinous borderline tumors [24,25]. This
emphasizes the importance of, and the need for more,
pooled analyses of individual-level data that are harmonized
carefully across different studies through collaborations
within consortia, such as OCAC. Clearly, the research com-
munity struggles to understand the causes of the majority
of these elusive and deadly cancers.
The strengths of this investigation include the analysis
of individual-level data from a large sample as well as
evaluation of higher levels of intakes (>3 drinks/d) and
the standardized method of alcohol analysis, which
allowed us to quantify risk associations based on average
daily grams of alcohol intake. Although we attempted to
reduce potential misclassification of histologic type by
applying a pathology-based algorithm, the associations
were not appreciably different if the algorithm was not
implemented, unlike previous analyses for other expo-
sures where implementation of the algorithm appeared
to refine those associations [69]. The large sample of
histologic types permitted evaluation of a wider range of
alcohol intake, particularly total alcohol and wine intake.
While a potential limitation of all case-control studies is
recall and selection bias, our pooled estimates are in
agreement with other reports [36,38]. Furthermore, al-
though our findings relating moderate alcohol intake
near the time of diagnosis indicated no association with
ovarian carcinoma, it is possible that alcohol intake at
other points in the life cycle may influence risk, given
the long latency period estimated for these cancers [89].
Conclusions
In conclusion, the results of this investigation do not
support an association between recent moderate total al-
cohol intake and ovarian carcinoma overall. The findings
do not strongly support variation in risk associated with
specific histologic types. Understanding the modifiable
causes of these deadly cancers through rigorous consor-
tium analyses remains a priority for the research
community.
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